LIFECORE BIOMEDICAL, INC. Derivative Liability, Noncurrent
LIFECORE BIOMEDICAL, INC. (LFCR) had Derivative Liability, Noncurrent of $30.92 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DerivativeLiabilitiesNoncurrent · last filed 2026-08-05
- 2026-06-30: Derivative Liability, Noncurrent $30.92M.
- 2026-03-31: Derivative Liability, Noncurrent $29.72M.
- 2025-12-31: Derivative Liability, Noncurrent $26.56M.
- 2025-09-30: Derivative Liability, Noncurrent $25.49M.
| Period end | Derivative Liability, Noncurrent |
|---|---|
| 2026-06-30 | $30.92M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $29.72M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $26.56M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $25.49M 10-Q · filed 2025-11-06 |
| 2025-05-25 | $24.99M 10-KT · filed 2026-03-16 |
| 2025-02-23 | $23.90M 10-Q · filed 2025-04-03 |
| 2024-11-24 | $23.30M 10-Q · filed 2025-01-02 |
| 2024-08-25 | $24.50M 10-Q · filed 2024-10-04 |
| 2024-05-26 | $25.40M 10-KT · filed 2026-03-16 |
| 2024-02-25 | $23.00M 10-Q · filed 2024-08-09 |
| 2023-11-26 | $44.00M 10-Q · filed 2024-08-09 |
| 2023-08-27 | $64.70M 10-Q · filed 2024-08-09 |
| 2023-05-28 | $64.90M 10-K · filed 2024-08-26 |
| 2022-05-29 | $0.00 10-K · filed 2024-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |